The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World

Table 3

Practice patterns in ulcerative colitis with infliximab. Results are presented as percentages or median (interquartile range) as appropriate.

	North America	Europe	Elsewhere	p-value
	N=183	N=103	N=58
Percentage of the time Anti-TNF used	20 (5-30)	10 (5-23)	5 (2-10)	<0.001
Anti-TNF sometimes used without IM trial
Steroid-dependent	76%	47%	36%	<0.001
Percentage of time combination IM used with anti-TNF
IM-naïve	50 (0-90)	85 (15-100)	90 (25-100)	0.002
After IM-failure	80 (20-100)	95 (50-100)	100 (50-100)	0.003
Thiopurine always or usually chosen as combination IM	35%	100%	86%	<0.001
Combination IM continued indefinitely	44%	15%	29%	0.004
Always adhere to standard induction
Steroid-refractory	46%	73%	61%	0.002
Steroid-dependent	70%	90%	78%	0.002